Clinical trials: Malignant Glioma of Brain
Glioblastoma, IDH-wildtype, Glioblastoma
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site.
- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant
- Trial name
- RECMAP (NCT06273176)
- Testing
- Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 225 people
- Sponsor
- Erasmus Medical Center
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
GBM, DIPG Brain Tumor
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Primary brain malignant tumor has become the first lethal tumor in children and young adults, and the treatment is limited, and the prognosis of patients is poor.
- Conditions
- GBM, DIPG Brain Tumor, Medulloblastoma
- Trial name
- CSAγδTBMG (NCT06396481)
- Testing
- Vγ9Vδ2 T cell
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma, Glioblastoma, IDH-wildtype
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70).
- Conditions
- Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Trial name
- RESBIOP (NCT06146725)
- Testing
- Tumor resection, Tumor biopsy
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 564 people
- Sponsor
- Jasper Gerritsen
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00994500
- Testing
- vorinostat, bortezomib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Glioma, Malignant
Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs
In patients operated for glioblastoma, glioma stem-like cell lines will be obtained from tumor tissue, and IPSCs from skin fibroblasts or PBMCs.
- Trial name
- 2253 (NCT05772741)
- Testing
- Biological sample collection
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
High Grade Glioma, Glioblastoma
Use of Fluorescence in Gliomas
During brain tumor surgery, it can be difficult for surgeons to distinguish between tumor tissue and healthy brain tissue. To address this challenge, fluorescent agents such as sodium fluorescein or 5-ALA are sometimes used.
- Conditions
- High Grade Glioma, Glioblastoma, Brain Neoplasms
- Trial name
- UFGAG (NCT07499141)
- Testing
- data collection
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Glioblastoma, Anaplastic Astrocytoma
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma
- Trial name
- NCT02800486
- Testing
- Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
High Grade Gliomas, Glioblastoma
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well.
- Conditions
- High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- PRC (NCT07439172)
- Testing
- Pre-radiation temozolomide.
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cooper Health System
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells.
- Trial name
- ATTAC (NCT00639639)
- Testing
- tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Gary Archer Ph.D.
Malignant Glioma, Astrocytoma
Nivolumab With DC Vaccines for Recurrent Brain Tumors
Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until…
- Conditions
- Malignant Glioma, Astrocytoma, Glioblastoma
- Trial name
- AVERT (NCT02529072)
- Testing
- nivolumab, DC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Gary Archer Ph.D.
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Childhood Brain Tumor
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
RATIONALE: Current therapies for children with primary malignant brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of…
- Trial name
- NCT00003476
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Brain and Central Nervous System Tumors
Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing…
- Trial name
- NCT00990652
- Testing
- Bortezomib, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Advanced Cancer, Brain Involvement
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and…
- Trial name
- DM-CHOC-PEN (NCT01048008)
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- DEKK-TEC, Inc.
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma, Adult Medulloblastoma, Adult Noninfiltrating Astrocytoma
- Trial name
- NCT00019578
- Testing
- Sterotactic radiosurgery
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain and Central Nervous System Tumors
Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of immunotoxin therapy and to see how well it works in treating…
- Trial name
- NCT00053040
- Testing
- cintredekin besudotox, conventional surgery
- Sponsor
- Pediatric Brain Tumor Consortium
Glioma, Anaplastic Astrocytoma
Dendritic Cell Vaccine for Patients With Brain Tumors
The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
- Trial name
- NCT01204684
- Testing
- autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Glioma of Brain, Colorectal Carcinoma
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Malignant Glioma of Brain, Colorectal Carcinoma, Gastric Carcinoma
- Trial name
- NCT02617134
- Testing
- anti-MUC1 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.